Pembrolizumab vs Streptococcus Pneumoniae Polysaccharide Conjugated To Haemophilus Influenzae Protein D

## Pembrolizumab vs Streptococcus Pneumoniae Polysaccharide Conjugated To Haemophilus Influenzae Protein D: Overview

This comparison examines the pharmacological differences between **Pembrolizumab** and **Streptococcus Pneumoniae Polysaccharide Conjugated To Haemophilus Influenzae Protein D**.

## Mechanism of Action

**Pembrolizumab**: Anti-PD-1 monoclonal antibody restoring anti-tumor immunity.

## Pharmacokinetics

**Half-life**: Pembrolizumab — 26 days; Streptococcus Pneumoniae Polysaccharide Conjugated To Haemophilus Influenzae Protein D — N/A.

## Chemical Properties

**Type**: Pembrolizumab — Antibody; Streptococcus Pneumoniae Polysaccharide Conjugated To Haemophilus Influenzae Protein D — Vaccine component.